COMPARATIVE ESTIMATE OF SOME TUMOR MARKERS IN FEMALES WITH COLON CANCER: A CLINICAL STUDY IN MOSUL CITY
Downloads
Objective: This study seeks to identify tumor parameters that help detect the different stages of malignant tumors. Method: Blood samples were gathered from 43 females undergoing colonoscopies in hospitals across Mosul, and 18 individuals who were healthy. After colectomy for cancer, the malignant tumor samples were divided into three groups depending on the tumor stages and tested using the ELISA method, with comparison control groups. Results: The ratios such as L/M and P/L showed meaningful differences between stages, which provides differences in the immune system response of patients. In early-stage cancer, markers like Septin-9, HIF-1α, and cf-DNA showed significant differences by tumor stage in women in identifying colon cancer progression. Novelty: The diagnosis and development of colon cancer can be understood with the help of VCAM-1, Septin-9, HIF-1α, and cf-DNA.
C. Krakstad, “Symptoms of cancer,” Allied J. Med. Res., vol. 5, no. 4, p. 7, 2021. [Online]. Available: https://www.cancer.gov/about-cancer/diagnosis-staging/symptoms
S. M. Y. Al-Taee and R. G. M. Al-Allaff, “A new strategy to evaluate emerging tumour-associated antigens as biomarkers of acute lymphocytic leukaemia development,” J. Appl. Nat. Sci., vol. 17, no. 1, pp. 179–185, 2025. https://doi.org/10.31018/jans.v17i1.6211
N. Boaretto et al., “Câncer: Uma Revisão Integrativa Por Estudantes De Medicina,” Bol. Curso Med. UFSC, vol. 9, no. 2, pp. 31–37, 2023. https://doi.org/10.32963/bcmufsc.v9i2.6402
S. K. Yadav and S. Srivastava, “Recent advancement in cancer treatment,” Eur. J. Appl. Sci., vol. 6, no. 3, pp. 37–44, 2014. https://doi.org/10.5829/idosi.ejas.2014.6.3.85145
A. Martínez-Gutierrez et al., “A microRNA panel that regulates proinflammatory cytokines as diagnostic and prognosis biomarkers in colon cancer,” Biochem. Biophys. Rep., vol. 30, p. 101252, 2022. https://doi.org/10.1016/j.bbrep.2022.101252
T. H. Lee, J. S. Kim, S. J. Baek, J. M. Kwak, and J. Kim, “Diagnostic Accuracy of Carcinoembryonic Antigen (CEA) in Detecting Colorectal Cancer Recurrence Depending on Its Preoperative Level,” J. Gastrointest. Surg., vol. 27, no. 8, pp. 1694–1701, 2023. https://doi.org/10.1007/s11605-023-05761-2
M. S. Reimers, E. C. M. Zeestraten, P. J. K. Kuppen, G. J. Liefers, and C. J. H. van de Velde, “Biomarkers in precision therapy in colorectal cancer,” Gastroenterol. Rep., vol. 1, no. 3, pp. 166–183, 2013. https://doi.org/10.1093/gastro/got022
L. R. Zarour et al., “Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions,” Cell. Mol. Gastroenterol. Hepatol., vol. 3, no. 2, pp. 163–173, 2017. https://doi.org/10.1016/j.jcmgh.2017.01.006
H. L. Al-Hayali, “Effect of hypervitaminosis d3 on liver, kidney functions in white rats,” Int. J. Res. Pharm. Sci., vol. 11, no. 4, pp. 5691–5700, 2020. https://doi.org/10.26452/ijrps.v11i4.3212
T. M. Al-Mushhadani, H. L. Al-Hayali, and S. O. Mostafa, “Synergistic effect of Rosemary and Lemon extractions on some physiological and biochemical parameters of CCl4-Stressed male rats,” Rev. Bionatura, vol. 8, no. 1, p. 64, 2023. https://doi.org/10.21931/RB/2023.08.01.64
P. Yousif, P. Ismail, and L. Hassan, “Estimation of the Levels of UDP Glucuronosyltransferase 2 Activity and some Vitamins (B12, B17, C and D) for Patients with Colon Cancer,” Rafidain J. Sci., vol. 33, no. 1, pp. 1–9, 2024. https://doi.org/10.33899/rjs.2024.182820
S. M. Y. Al-Taee and R. G. M. Al-Allaff, “Soluble HLA-G as a Novel Biomarker for the Diagnosis of Acute Lymphoblastic Leukemia,” Turk. J. Immunol., vol. 13, no. 1, pp. 55–62, 2025. https://doi.org/10.36519/tji.2025.567
K. A. VanHeys, S. H. Choi, D. T. Kingsley, and A. Y. Huang, “Therapy Resistance,” Cells, vol. 11, no. 23, p. 3922, 2022. https://doi.org/10.3390/cells11233922
R. Mirzaee, “Molecular genetics discovery and functional genomics in sudden cardiac death syndromes linked with inherited in arrhythmia in short QT syndrome,” J. Mol. Genet. Med., vol. 11, no. 4, p. 35, 2017. https://doi.org/10.4172/1747-0862-c1-020
A. Yildiz et al., “Septin-9: a novel biomarker for colorectal cancer screening,” Int. Surg. J., vol. 6, no. 2, pp. 355–360, 2019. https://doi.org/10.18203/2349-2902.isj20190382
M. Fischer, D. Frank, R. Rösler, N. Johnsson, and T. Gronemeyer, “Biochemical Characterization of a Human Septin Octamer,” Front. Cell Dev. Biol., vol. 10, p. 771388, 2022. https://doi.org/10.3389/fcell.2022.771388
A. A. Rawłuszko-Wieczorek, K. Horbacka, P. Krokowicz, M. Misztal, and P. P. Jagodziński, “Prognostic potential of DNA methylation and transcript levels of HIF1A and EPAS1 in colorectal cancer,” Mol. Cancer Res., vol. 12, no. 8, pp. 1112–1127, 2014. https://doi.org/10.1158/1541-7786.MCR-14-0054
X. Chai et al., “Expression of HIF-1α, ANXA3, CD133 and their associations with clinicopathological parameters in human colon carcinoma,” Transl. Cancer Res., vol. 11, no. 6, pp. 1644–1651, 2022. https://doi.org/10.21037/tcr-22-1277
S. Grabuschnig et al., “Circulating cell-free DNA is predominantly composed of retrotransposable elements and non-telomeric satellite DNA,” J. Biotechnol., vol. 313, pp. 48–56, 2020. https://doi.org/10.1016/j.jbiotec.2020.03.002
W. Li et al., “5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers,” Cell Res., vol. 27, no. 10, pp. 1243–1257, 2017. https://doi.org/10.1038/cr.2017.121
V. M. Papadakis et al., “Label-Free Human Disease Characterization through Circulating Cell-Free DNA Analysis Using Raman Spectroscopy,” Int. J. Mol. Sci., vol. 24, no. 15, p. 12384, 2023. https://doi.org/10.3390/ijms241512384
T. S. Jalolov, “Use of SPSS Software in Psychological Data Analysis,” Psixologiya va Sotsiologiya Ilmiy Jurnali, vol. 2, no. 7, pp. 1–6, 2024.
T. Niedermaier et al., “To what extent is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results from a large German screening population,” Int. J. Cancer, vol. 149, no. 11, pp. 1877–1886, 2021. https://doi.org/10.1002/ijc.33742
M. A.-R. Mohammad, S. R. Abdelwahed, K. A. Eid, and H. M. Mostafa, “Comprehensive study between conventional colonoscopy and virtual CT colonography in assessment of colonic disorders,” Int. J. Adv. Res. Med., vol. 5, no. 2, pp. 126–133, 2023. https://doi.org/10.22271/27069567.2023.v5.i2b.490
L. Wan, C. Wu, S. Luo, and X. Xie, “Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors,” Dis. Markers, vol. 2022, pp. 1–20, 2022. https://doi.org/10.1155/2022/3610038
G. Turri et al., “Prediagnostic prognostic value of leukocytes count and neutrophil-to-lymphocyte ratio in patients who develop colorectal cancer,” Front. Oncol., vol. 13, p. 1148197, 2023. https://doi.org/10.3389/fonc.2023.1148197
T. Yamamoto, K. Kawada, and K. Obama, “Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients,” Int. J. Mol. Sci., vol. 22, no. 15, pp. 1–14, 2021. https://doi.org/10.3390/ijms22158002
P. S. Virdee et al., “The full blood count blood test for colorectal cancer detection: A systematic review, meta-analysis, and critical appraisal,” Cancers, vol. 12, no. 9, pp. 1–34, 2020. https://doi.org/10.3390/cancers12092348
T. Hayama et al., “Impact of colon cancer location on the prognostic significance of nutritional indexes and inflammatory markers,” In Vivo, vol. 35, no. 2, pp. 1261–1269, 2021. https://doi.org/10.21873/invivo.12377
L. Abd El Kader, A. H. Soliman, S. E. Salem, S. Y. Akel, and N. H. Ibrahim, “The Clinical Significance of Septin 9 and Colon Cancer Specific Antigen-2 (CCSA-2) in Colorectal Cancer,” Asian Pac. J. Cancer Prev., vol. 24, no. 3, pp. 1027–1036, 2023. https://doi.org/10.31557/APJCP.2023.24.3.1027
C. Lisanti et al., “The SAFFO Study: Sex-Related Prognostic Role and Cut-Off Definition of Monocyte-to-Lymphocyte Ratio (MLR) in Metastatic Colorectal Cancer,” Cancers, vol. 15, no. 175, pp. 1–12, 2023. https://doi.org/10.3390/cancers15010175
X. Ye and W. Mi, “Analysis of the Peripheral Blood Helper T-Cell 17-Cell Level and Monocyte/Lymphocyte Ratio for Colorectal Cancer Prognosis Prediction,” Proc. Anticancer Res., vol. 8, no. 3, pp. 133–137, 2024. https://doi.org/10.26689/par.v8i3.6660
F. A. Mohammad, “Isolation and Studying the Activity and Properties of Adenosine Deaminase (ADA) in Patients Tissues of Benign and Malignant Colon Tumors,” Rafidain J. Sci., vol. 23, no. 3, pp. 117–130, 2012. https://doi.org/10.33899/rjs.2012.44402
L. F. Bdaiwi, “The Properties of Protease Isolated from Tissues of Benign and Malignant Kidney Tumors Patients,” Rafidain J. Sci., vol. 24, no. 7, pp. 13–24, 2013. https://doi.org/10.33899/rjs.2013.77812
N. Azeez, S. Sulayman, and I. Adel, “Colon Cancer Early Detection by some Serum’s Antigenic, Enzymatic and Free-serum’s DNA indicators,” Rafidain J. Sci., vol. 27, no. 4, pp. 114–127, 2018. https://doi.org/10.33899/rjs.2018.159343
D. Zhang et al., “VCAM1 Promotes Tumor Cell Invasion and Metastasis by Inducing EMT and Transendothelial Migration in Colorectal Cancer,” Front. Oncol., vol. 10, p. 1066, 2020. https://doi.org/10.3389/fonc.2020.01066
J. Okletey, D. Angelis, T. M. Jones, C. Montagna, and E. T. Spiliotis, “An oncogenic isoform of septin 9 promotes the formation of juxtanuclear invadopodia by reducing nuclear deformability,” Cell Rep., vol. 42, no. 8, p. 112893, 2023. https://doi.org/10.1016/j.celrep.2023.112893
T. Peng, F. Kong, X. Diao, J. Huang, and X. Liu, “Septin 9 hypermethylation contributes to migration and resistance to drug treatments in colon cancer,” Trop. J. Pharm. Res., vol. 16, no. 4, pp. 803–810, 2017. https://doi.org/10.4314/tjpr.v16i4.9
J. Sun et al., “The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer,” BMC Cancer, vol. 19, no. 1, p. 5663, 2019. https://doi.org/10.1186/s12885-019-5663-8
M. Leon Arellano et al., “A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene,” Dis. Markers, vol. 2020, pp. 1–5, 2020. https://doi.org/10.1155/2020/9761406
Q. Qu and Q. Sun, “Diagnostic value of new combination of methylated Septin9 with LMR in adenomatous polyps and stage I to IV colorectal cancer,” Res. Square, pp. 1–13, 2023. https://doi.org/10.21203/rs.3.rs-2816055/v1
P. Pandey et al., “Recent Update of Natural Compounds as HIF-1 α Inhibitors in Colorectal Carcinoma,” Drug Des. Devel. Ther., vol. 19, pp. 2017–2034, 2025. https://doi.org/10.2147/DDDT.S511406
P. Chen et al., “Identification of Hypoxia-Associated Signature in Colon Cancer to Assess Tumor Immune Microenvironment and Predict Prognosis Based on 14 Hypoxia-Associated Genes,” Int. J. Gen. Med., vol. 16, pp. 2503–2518, 2023. https://doi.org/10.2147/IJGM.S407005
B. Smolarz et al., “Hypoxia-induced Factor-1α and its Role in Endometrial Cancer,” Anticancer Res., vol. 44, no. 9, pp. 3697–3712, 2024. https://doi.org/10.21873/anticanres.17195
M. Noë et al., “DNA methylation and gene expression as determinants of genome-wide cell-free DNA fragmentation,” Nat. Commun., vol. 15, no. 1, p. 6690, 2024. https://doi.org/10.1038/s41467-024-50850-8
A. Chidharla et al., “Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis,” Int. J. Mol. Sci., vol. 24, no. 12, p. 10230, 2023. https://doi.org/10.3390/ijms241210230
M. Elbaiomy and M. Sabry, “P-8 Circulating tumor DNA could have impact on risk assessment and personalizing adjuvant therapy in localized colon cancer,” Ann. Oncol., vol. 34, p. S16, 2023. https://doi.org/10.1016/j.annonc.2023.04.064
Y. Hu et al., “Molecular alterations in circulating cell-free DNA in patients with colorectal adenoma or carcinoma,” Cancer Manag. Res., vol. 12, pp. 5159–5167, 2020. https://doi.org/10.2147/CMAR.S244520
Copyright (c) 2025 Shaimaa Obaid Mostafa, Haitham L Al-Hayali , Mowafak K Hasan
This work is licensed under a Creative Commons Attribution 4.0 International License.
